{
    "clinical_study": {
        "@rank": "18446", 
        "arm_group": [
            {
                "arm_group_label": "BIA 9-1067", 
                "arm_group_type": "Active Comparator", 
                "description": "multiple rising dose regimens  (5, 10, 20 and 30 mg) of BIA 9-1067 5 mg capsules. Oral, once-daily (QD) in the morning during 8 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching 5 mg capsules. Oral, QD in the morning during 8 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the tolerability of BIA 9-1067 after multiple rising\n      dose regimens of BIA 9-1067."
        }, 
        "brief_title": "Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067", 
        "completion_date": {
            "#text": "September 2008", 
            "@type": "Actual"
        }, 
        "condition": "Parkinson's Disease (PD)", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "detailed_description": {
            "textblock": "Single centre, double-blind, randomised, placebo-controlled study of four dosage regimens of\n      BIA 9-1067 in four groups of healthy male volunteers. In each group, the study will consist\n      of an once-daily (o.d.) 8-day multiple-dose period. Progression to the next dose level will\n      only occur if the previous dose level was considered to be safe and well tolerated. An\n      appropriate interval (will separate the investigation of doses to permit a timely review and\n      evaluation of safety data prior to proceeding to a higher dose level."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. A signed and dated informed consent form before any study-specific screening\n             procedure is performed.\n\n          2. Aged between 18 and 45 years, inclusive.\n\n          3. Healthy as determined by the investigator on the basis of medical history, physical\n             examination, clinical laboratory test results, vital signs and digital 12-lead\n             electrocardiogram (ECG).\n\n          4. Nonsmoker or smoker of fewer than 10 cigarettes per day as determined by history.\n             Must be able to abstain from smoking during the inpatient stay.\n\n        Exclusion Criteria:\n\n          1. Any significant cardiovascular (e.g. hypertension), hepatic, renal, respiratory (e.g.\n             childhood asthma), gastrointestinal, endocrine (e.g. diabetes, dyslipidemia),\n             immunologic, dermatological, haematological, neurologic, or psychiatric disease.\n\n          2. Acute disease state (e.g., nausea, vomiting, fever, diarrhoea) within 7 days before\n             study day 1.\n\n          3. History of drug abuse within 1 year before study day 1.\n\n          4. History of alcoholism within 1 year before day 1. Consumption of more than 50 g of\n             ethanol per day (12.5 cL glass of 10\u00b0 [10%] wine = 12 g; 4 cL of aperitif, 42\u00b0 [42%]\n             whiskey = 17 g; 25 cL glass of 3\u00b0 [3%] beer = 7.5 g; 25 cL glass of 6\u00b0 [6%] beer = 15\n             g\n\n          5. Have previously received BIA 9-1067.\n\n          6. Positive serologic findings for human immunodeficiency virus (HIV) antibodies,\n             hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies.\n\n          7. Positive findings of urine drug screen (eg, amphetamines, barbiturates,\n             benzodiazepines, cannabinoids, cocaine, methadone, opiates, MDMA\n             [3,4-methylenedioxy-methamphetamine; ecstasy]).\n\n          8. History of any clinically important drug allergy.\n\n          9. Prohibited Treatments: use of any investigational drug within 90 days or prescription\n             drug within 30 days before investigational medical product (IMP) administration.\n\n         10. Consumption of any caffeine-containing products (e.g., coffee, tea, chocolate, or\n             soda) in excess of 6 cups per day (or equivalent), of grapefruit,\n             grapefruit-containing products, or alcoholic beverages within 24 before study day 1.\n\n         11. Use of any over-the-counter drugs including herbal supplements (except for the\n             occasional use of acetaminophen [paracetamol], aspirin and vitamins \u2264100% recommended\n             daily allowance) within 7 days before IMP administration.\n\n         12. Donation of blood (ie 450 ml) within 90 days before study day 1."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02071810", 
            "org_study_id": "BIA-91067-102"
        }, 
        "intervention": [
            {
                "arm_group_label": "BIA 9-1067", 
                "intervention_name": "BIA 9-1067", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Parkinson's disease (PD)", 
            "Opicapone", 
            "Bial", 
            "BIA 9-1067"
        ], 
        "lastchanged_date": "February 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rueil", 
                    "country": "France", 
                    "state": "Malmaison", 
                    "zip": "F-92501"
                }, 
                "name": "BIOTRIAL"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-blind, Randomised, Placebo-controlled Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Four Multiple Rising Dose Regimens of BIA 9-1067 in Healthy Male Volunteers", 
        "overall_official": {
            "affiliation": "BIOTRIAL", 
            "last_name": "Dikran Mouradian, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "N\u00ba of treatment emergente adverse events (TEAEs) per subject", 
            "safety_issue": "Yes", 
            "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02071810"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Bial - Portela C S.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bial - Portela C S.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2008"
    }
}